Article Details
Retrieved on: 2024-02-19 20:01:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
This study in "The Lancet" reveals disparities in global access to direct-acting antivirals (DAAs) for Hepatitis C, with low reimbursement rates in LMICs, echoing socioeconomic and regulatory hurdles, but also underscoring the need to align with WHO's objectives for HCV elimination. The article relates to 'Criminal Law' in terms of addressing the legal and regulatory barriers affecting access to healthcare. The tags list chemical compounds and drugs involved in the discussed treatments.
Article found on: www.contagionlive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here